Inclisiran in Patients with CKD

Key Points

• Inclisiran achieves significant LDL cholesterol reduction, enhancing cardiovascular disease management.
• The treatment remains effective regardless of baseline eGFR, reaching levels as low as 15 mL/min/1.73m2.
• This assessment involved a diverse group of patients and monitored safety findings related to the drug.
• Overall, the findings support the use of inclisiran in wider CKD contexts, implying potential benefits for heart health.

Abstract